UNITY Biotechnology (NASDAQ:UBX) stock fell 30% after the company's mid-stage trial for its diabetic macular edema treatment did not meet main goal. The study showed that patients treated with UBX1325 ...

“Young blood” projects: Solid science continues with Grifols funded startup Alkahest, while less conservative Ambrosia is seeking paying patients for its anti-aging trial. Senolytics (Senescent cells) ...

UNITY Biotechnology, Inc. reported its financial results for the first quarter of 2025, highlighting the 24-week and partial 36-week topline data from its Phase 2b ASPIRE study in diabetic macular ...

UNITY Biotechnology has appointed Federico Grossi, M.D., Ph.D., as its new chief medical officer to enhance its leadership team. Dr. Grossi, who has over 20 years of experience in biotech, previously ...

SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today ...

(KRON) — The future of one biotech company on the Peninsula is drastically changing. Unity Biotechnology is laying off its entire workforce, the company announced Monday in a press release. The ...

This press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY ...

SOUTH SAN FRANCISCO, Calif., March 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...

Robert B. Bhisitkul, M.D., Ph.D., today, April 24 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY ...

Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) – Analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Unity Biotechnology in a research report issued on Monday, March 10th.

UNITY Biotechnology (UBX) announced that Yehia Hashad, M.D., executive vice president of research and development and chief medical officer at Bausch + Lomb, has been appointed to the Company’s board ...